The product, Elute’s EP Granules with Tobramycin, is a synthetic bone filler that provides an eight-week delivery of an antibiotic while allowing bone growth, according to a Nov. 30 news release. Orthopedic surgeons Amar Ranawat, MD, of HSS and Javad Parvizi, MD, of Rothman are clinical partners in the trial.
The trials come after EP Granules with Tobramycin received investigational device exemption authorization from the FDA.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
